DocMorris Reports Significant Q3 Rx Growth and Achieves EBITDA Breakeven

DocMorris AG has announced a 78% growth in prescription medicines (Rx) during Q3 2026, reaching an EBITDA breakeven with a CHF 0.6 million adjusted EBITDA. Revenue for the third quarter increased by 21.5% to CHF 342.7 million compared to the previous year. Non-Rx revenues grew by 5.5%, propelled by a 46.1% rise in Digital Services.

In Germany, Rx external revenue expanded by 78.3%, and non-Rx revenue saw a growth of 5.5%. Additionally, the number of active customers rose to 13.1 million. The company has raised its revenue and EBITDA forecasts for 2026, expecting external revenue growth between 12.5% and 15%.

DocMorris also successfully repurchased a CHF 49.6 million convertible bond, extending its maturity to 2031 and lowering finance costs. The company's performance underscores its strong footing in the digital healthcare market.